Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Two drugs. Two strategies. One industry in the middle of a rewiring.

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...